BTK and Miyoshi myopathy: The potential use of proteasome inhibition in combination with the BTK inhibitor ibrutinib (IBR) in MM has already entered clinical trials (ClinicalTrials.gov, NCT01962792), although we currently lack understanding of the molecular interactions between both targeted pathways.